BOSTON and NEW YORK, May 20, 2021: Morgan Lewis represented RenBio Inc. in closing a $24 million Series A investment and a license agreement with Columbia University for exclusive worldwide development and commercialization rights to a novel bispecific antibody for COVID-19.
Since 2016, RenBio has focused on leveraging the collective range of biological and engineering talents of its team to advance the company’s MYO technology platform and deliver antibodies for the prevention and treatment of multiple diseases. RenBio was co-founded by Drs. David Ho and Yaoxing Huang, scientists affiliated with the Aaron Diamond AIDS Research Center in New York City.
Morgan Lewis partners Michael Barron, Jay Carrigan, and Sarah-Jane Morin, and associates Sheri Yano, Esther Phu, Nicola Liu, and Ryan Montgomery represented RenBio.